Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Tania Nikolcheva, Gavin Giovannoni and Tharick Pascoal on the Special issue in Neurology
-
ナレーター：
-
著者：
In this episode of The Lancet In Conversation With, editors Niall Boyce and Bea Gómez Pérez-Nievas are joined by three leading researchers to discuss highlights from The Lancet's special issue on neurology. The conversation covers three landmark studies: the PADOVA trial of prasinezumab in early-stage Parkinson's disease, the ORATORIO-HAND study extending ocrelizumab treatment to wheelchair-using patients with progressivemultiple sclerosis, and the HEAD study comparing tau PET tracers in Alzheimer's disease — each representing a significant step forward in the field.
The guests also reflect on the broader forces reshaping neurology: the push toward earlier, biomarker-guided intervention, cross-specialty learning between the multiple sclerosis, Alzheimer's, and Parkinson's fields, and emerging platforms such as CAR T-cell therapies and blood-based biomarkers. From the transformative success of spinal muscular atrophy treatment to the prospect of an EBV vaccine preventing MS, the discussion strikes a note of cautious optimism about a specialty that is entering a new therapeutic era.
Visit the lancet.com to discover more